Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective diligently but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll ever be being used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the therapy of multi-drug-resistant HIV have been closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. The 1st CytoDyn post of mine, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire interview which I came away with a poor impression of the business.

Irony of irony, my poor viewpoint of the business has grown steadily, however, the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein sits the story; let me explain.

CytoDyn acquired its much-storied treatment (which I shall mean as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment as well as reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of the technology as well as associated intellectual property from Progenics to CytoDyn, and approximately twenty five million mg of bulk drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 million) and also the very first brand new drug program endorsement ($5 million), and even royalty payments of 5 % of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with multiple indications and numerous therapies, it’s this single remedy as well as a “broad pipeline of indications” since it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit centered on leronlimab, several disease types, multiple presentations in addition to multiple publications.

Might all this be smoke cigarettes and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this organization. Judging by the multiples of thousands of diverse remarks on listings accessible via Seeking Alpha’s CytoDyn Summary page, I’m a lot from alone in this question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *